Author

N. Heaton

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Bioengineering· 1 Microbiology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Research Focus:host-pathogen & immune response· 2 Research Focus:drug response / drug discovery· 1 Organism:human· 1

Frequent Co-Authors

A. Chemparathy· 1 shared A. Embry· 1 shared C. B. Wilen· 1 shared D. B. Lewis· 1 shared D. Endy· 1 shared G. Dhamdhere· 1 shared J. G. Doench· 1 shared L. E. Goudy· 1 shared

Activity by Year

2020-2023 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 24 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperBioengineering

A. Chemparathy

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Genome-wide CRISPR activation screen identifies JADE3 as an antiviral activator of NF-kB

M. Munir, A. Embry, J. G. Doench, N. Heaton, C. B. Wilen, R. Orchard

The paper identifies JADE3 as an antiviral activator of the NF-kB pathway through a CRISPR activation screen against influenza A virus.

bioRxiv · Sep 29, 2023 · PreprintMicrobiology

Development of CRISPR as a prophylactic strategy to combat novel coronavirus and influenza

T. R. Abbott, G. Dhamdhere, Y. Liu, X. Lin, L. E. Goudy, L. Zeng, A. Chemparathy, S. Chmura, N. Heaton, R. Debs, T. Pande, D. Endy, M. La Russa, D. B. Lewis, L. S. Qi

This paper develops a CRISPR-Cas13-based strategy called PAC-MAN to inhibit SARS-CoV-2 and influenza A virus in human cells, showing it can degrade viral sequences and reduce replication.

bioRxiv · Mar 13, 2020 · PreprintBioengineering